Melanotan II: Melanocortin Tanning and Pigmentation Research

Research Disclaimer: Melanotan II is sold exclusively for in-vitro and laboratory research use. Not for unsupervised use. This content does not constitute medical advice.

Melanotan II (MT-II; Ac-Nle⁴-cyclo[Asp⁵, D-Phe⁷, Lys¹⁰]-α-MSH(4-10)-NH₂) is a synthetic cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH). Developed at the University of Arizona (Hadley group, 1980s) as a photoprotective agent, MT-II activates MC1R in melanocytes to stimulate eumelanin production — providing photoprotection independent of UV exposure. MT-II also activates MC3R, MC4R, and MC5R, giving it broader pharmacology than selective MC1R agonists. Research applications span melanogenesis, photoprotection, sexual behavior (MC4R), appetite (MC4R), and inflammation.

Table of Contents#

1. Structure: α-MSH Analogue Design
2. Melanocortin Receptors: MT-II Binding Profile
3. MC1R and Melanogenesis Mechanism
4. Photoprotection Research
5. Non-Melanogenic Effects: MC4R, MC3R
6. Pharmacokinetics
7. MT-II vs. Afamelanotide (Scenesse)
8. Research Protocols
9. Key References

Structure: α-MSH Analogue Design#

MT-II = Ac-Nle⁴-cyclo[Asp⁵, D-Phe⁷, Lys¹⁰]-α-MSH(4-10)-NH₂:

• Core: HFRWG tetrapeptide (His-Phe-Arg-Trp-Gly → His-D-Phe-Arg-Trp core is the pharmacophore)
• Nle⁴ substitution: Norleucine replaces Met⁴ → prevents methionine oxidation → improved stability
• D-Phe⁷: D-phenylalanine → increased metabolic stability, higher receptor affinity
• Cyclization (Asp⁵-Lys¹⁰ side-chain amide bridge): constrains conformation → markedly increased receptor binding and duration of action vs. linear α-MSH
• MW ~1024 Da

Design principle: natural α-MSH (13 amino acids, linear) has t½ ~minutes. MT-II's cyclization and D-amino acid substitutions extend t½ to hours and increase MC1R affinity by orders of magnitude.

Melanocortin Receptors: MT-II Binding Profile#

MT-II is relatively non-selective among MCR subtypes:

Research implication: MT-II's non-selective MCR profile means researchers cannot attribute effects to a single receptor. For pure MC1R research: use α-MSH (MC1R > others) or afamelanotide (MC1R-selective analog). For MC4R research: use PT-141 (more selective for MC3R/MC4R).

MC1R and Melanogenesis Mechanism#

MC1R signaling cascade:

1. MT-II → MC1R (Gs-coupled) → adenylyl cyclase → cAMP ↑ → PKA activation
2. PKA → MITF (microphthalmia-associated transcription factor) phosphorylation/stabilization
3. MITF → activates promoters of melanogenic enzymes:
   • Tyrosinase (TYR): rate-limiting step; converts tyrosine → DOPA → dopaquinone
   • TYRP1 (tyrosinase-related protein 1): converts dopachrome → DHICA melanin
   • DCT/TYRP2: stabilizes TYRP1
4. Melanosomes: mature melanosomes produced, transferred to keratinocytes via dendrite contacts
5. Keratinocytes: melanosomes distributed in supra-nuclear cap → UV protection

Eumelanin vs. phaeomelanin switch:

• MC1R activation → PKA → shifts melanocytes from phaeomelanin (yellow/red, UV-generating) to eumelanin (brown/black, UV-absorbing, photoprotective)
• This switch is the fundamental pharmacological action of MT-II and α-MSH agonists

Photoprotection Research#

UV-independent tanning:

• MT-II stimulates melanogenesis without UV exposure
• This is significant for photoprotection research: UV-induced tanning (phaeomelanin first, eumelanin later) causes DNA damage on the way to protection
• MT-II-induced eumelanin synthesis before UV exposure provides photoprotection without the initial UV-damage phase

EPP model (erythropoietic protoporphyria):

• MT-II/afamelanotide increase skin melanin → reduced photosensitivity in light-sensitive porphyria patients
• Research model: Fech(m1Pas) mice (EPP mouse model) → afamelanotide/MT-II → reduced phototoxicity, improved sun exposure tolerance

Skin cancer prevention hypothesis:

• MC1R variants (red hair phenotype, fair skin, low MC1R signaling) → higher melanoma risk
• MC1R agonism hypothesis: restoring MC1R signaling → shift to eumelanin → reduced UV-induced DNA damage → theoretical cancer prevention
• Research status: preclinical support; human RCT data insufficient to establish prevention

Non-Melanogenic Effects: MC4R, MC3R#

MT-II's MC4R activity produces effects beyond pigmentation:

Appetite/energy balance (MC3R + MC4R):

• MT-II injection → acutely reduces food intake in rodents (MC4R pathway)
• Agouti-yellow mice (constitutive MC4R antagonism by agouti protein): obese, impaired MT-II appetite suppression → MC4R required for this effect

Sexual behavior (MC4R):

• MT-II produces ex copula penile erections in rats at doses lower than its melanogenic doses
• This was the initial observation that led to PT-141 development — researchers testing MT-II for tanning in a human volunteer observed unexpected erections
• Research interest: separating MC1R (melanogenic) from MC4R (sexual/appetite) effects requires selective compounds

Blood pressure (MC4R in brainstem):

• Acute MT-II injection → blood pressure and heart rate increase
• Mediated by MC4R in nucleus tractus solitarius and rostral ventrolateral medulla
• Research consideration: include blood pressure monitoring in MT-II rodent studies

Pharmacokinetics#

MT-II vs. Afamelanotide (Scenesse)#

Afamelanotide (NDP-α-MSH, Scenesse by Clinuvel) is the only FDA/EMA-approved melanocortin for clinical use (EPP indication):

Research Protocols#

Melanogenesis dose-response (B16-F10 mouse melanoma cells)#

UV-independent tanning in guinea pigs (photoprotection model)#

Key References#

1. Hadley ME & Dorr RT. (2006). "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides, 27(4):921–930.

2. Böhm M, et al. (2005). "Evidence for a direct pro-melanogenic effect of α-MSH on human melanocytes." Journal of Investigative Dermatology, 124(5):1000–1007.

3. Langan EA, et al. (2010). "Melanocortin receptor pharmacology." Current Pharmaceutical Design, 16(9):1002–1019.

Research Use Only: Melanotan II is sold exclusively for in-vitro research and laboratory use. Not for unsupervised use. JuicedPharma does not provide medical advice.

Published by JuicedPharma Research Team · September 2026 · Category: Peptides & Recovery